Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR For Women with Breast Cancer, Regular Exercise May Improve Survival May 15, 2020 How to Cope With and Discuss an Uncertain Cancer Prognosis: An... September 7, 2023 No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia July 30, 2021 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Load more HOT NEWS What Do “Health Equity” and “Quality Care” Mean in Cancer Care? Breast Cancer Survivor Driven from Her Home by Noxious Gases from... Breast Cancer May Spread by Recruiting Nearby Sensory Nerves FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
